Starch and albumin mixture as replacement fluid in therapeutic plasma exchange is safe and effective.

UNLABELLED: Therapeutic plasma exchange (TPE) is an effective treatment in Myasthenia gravis (MG) and Guillain-Barré syndrome (GBS) and 5% human albumin is the replacement fluid of choice; however, it is expensive. More recently, it has been suggested that starch is a safe and cheaper choice to human albumin. OBJECTIVE: To evaluate our 5-year experience using 3% hydroxyethyl starch (HES) and 5% human albumin mixture, as replacement fluid in TPE for these diseases. MATERIALS AND METHODS: Retrospective study carried out from January 2001 through September 2006. We included those patients with MG and GBS undergoing TPE. We analyzed clinical outcome (CO) and adverse events (AE) and our results were compared with a previous study which included similar patients undergoing TPE using just 5% human albumin. RESULTS: Thirty-one procedures were carried out in 26 patients, a total of 147 TPE sessions. In the group of MG we had 57% complete responses (CR) and 86% overall response (OR) while in the group of GBS we had 40% CR and 60% OR. When we analyzed our CO with the previous study no statistical differences were found. Mean processed plasma volume (PPV) was 4.2 in MG and 5.5 in GBS. Twenty patients had AE, being hypotension and catheter dysfunction the most frequent ones, while tachycardia, hypertension and paresthesias were statistically more frequent in the HES/albumin group. CONCLUSIONS: TPE with a mixture of 3% HES and 5% human albumin is as effective and safe as 5% human albumin alone for patients with these diseases.

Therapeutic plasma exchange in Mexico: experience from a single institution.

Information about therapeutic plasma exchange (TPE) in developing countries is lacking. We report our experience with TPE performed for different indications during a 7-year period. We reviewed all TPE procedures performed in our institution during a 7-year period. Patients were divided in four groups according to the following indications: thrombotic microangiopathies (TM), myasthenia gravis (MG), polyneuropathies (PNP), and miscellaneous indications (MI). Clinical outcome (CO) and complications were evaluated. Eighty-seven procedures were carried out in 81 patients, for a total of 376 TPE sessions. Eighty-two procedures were analyzed for CO. In the group of TM we had 65% overall response rate (ORR): 35% complete response (CR) and 30% partial response (PR). Six (28.6%) patients died in this group. In the MG group we had 90% ORR: 69% CR and 21% PR. In the PNP group we had 78% ORR: 56% CR and 22% PR. In the MI group we had 92% ORR: 59% CR and 33% PR. We observed 47 adverse reactions in 40 (46%) procedures performed in 38 (47%) patients. This represented 12.5% of sessions. We had seven major complications leading to TPE discontinuation; this represented 8% of the procedures and 1.8% of sessions. One patient (0.2%) died during TPE. Our overall results are acceptable. In the TM group our results are somewhat lower than in other published reports, but in MG and PNP our results are similar to other published reports. Our complication rate is similar to that reported by others. Careful selection of patients and protocols is crucial to achieve maximum benefit from TPE programs in countries where plasmapheresis facilities are not widely available.